[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alto Neuroscience Inc (ANRO)

Alto Neuroscience Inc (ANRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Alto Neuroscience Prepares to Report Another Loss While Analysts Lower Their Gaze

Alto Neuroscience Inc (ANRO) reports Q2 2026 earnings tomorrow, August 12, 2026, with analysts expecting a loss of $0.71 per share. The central question is whether the clinical-stage biopharmaceutical company can reverse the sharp deterioration seen last quarter, when it missed estimates by 43% and posted its worst loss in over a year. With analyst sentiment weakening and estimates rising significantly over the past 90 days, investors face a critical test of whether ANRO's precision psychiatry platform can regain credibility after a disappointing start to 2026.

Alto Neuroscience is a clinical-stage biopharmaceutical company developing precision psychiatry treatments using biomarker-based patient selection to improve outcomes in major depressive...

Fundamentals

See More
  • Market Capitalization, $K 1,010,005
  • Shares Outstanding, K 35,094
  • Annual Sales, $ 0 K
  • Annual Income, $ -63,240 K
  • EBIT $ -78 M
  • EBITDA $ -77 M
  • 60-Month Beta 1.06
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.76

Options Overview Details

View History
  • Implied Volatility 96.73% (+7.54%)
  • Historical Volatility 56.61%
  • IV Percentile 13%
  • IV Rank 3.88%
  • IV High 552.79% on 09/10/25
  • IV Low 78.34% on 04/21/26
  • Expected Move (DTE 9) 1.23 (4.28%)
  • Put/Call Vol Ratio 0.67
  • Today's Volume 30
  • Volume Avg (30-Day) 49
  • Put/Call OI Ratio 0.59
  • Today's Open Interest 1,143
  • Open Int (30-Day) 1,161
  • Expected Range 27.55 to 30.01

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.71
  • Number of Estimates 5
  • High Estimate $-0.57
  • Low Estimate $-0.81
  • Prior Year $-0.65
  • Growth Rate Est. (year over year) -9.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.50 +12.86%
on 07/13/26
29.49 -2.41%
on 08/06/26
+2.30 (+8.69%)
since 07/10/26
3-Month
17.90 +60.78%
on 06/08/26
29.49 -2.41%
on 08/06/26
+4.25 (+17.33%)
since 05/11/26
52-Week
3.02 +852.98%
on 08/14/25
29.49 -2.41%
on 08/06/26
+25.72 (+840.52%)
since 08/11/25

Most Recent Stories

More News
Alto Neuroscience Prepares to Report Another Loss While Analysts Lower Their Gaze

Barchart Research What to Expect from ANRO Earnings ANRO Generated August 11, 2026 Current Price $28.78 EPS Estimate $$-0.71 Consensus Rating Strong Buy Average Move 6.41% Alto Neuroscience Prepares to...

ANRO : 28.78 (+1.73%)
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective...

ANRO : 28.78 (+1.73%)
Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia

– Independent, peer-reviewed, placebo-controlled trial conducted by Lund University showed pramipexole significantly reduced anhedonia (primary endpoint, Hedges’ g=0.62, p=0.006) – ...

ANRO : 28.78 (+1.73%)
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors

Miller brings deep neuropsychiatry drug development and value creation experience, having led R&D at Karuna Therapeutics through its $14 billion acquisition by Bristol Myers Squibb

ANRO : 28.78 (+1.73%)
Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award

Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today congratulates founder and...

ANRO : 28.78 (+1.73%)
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights

– Phase 2b clinical trial of ALTO-207 in treatment-resistant depression (TRD) initiated – – New ALTO-101 analyses support significant effects on EEG markers of general...

ANRO : 28.78 (+1.73%)
Alto Neuroscience Announces Participation in Upcoming Investor Conferences

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that...

ANRO : 28.78 (+1.73%)
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting

— Randomized, placebo-controlled, Phase 2a trial demonstrated robust, statistically significant antidepressant effects of ALTO-207 and favorable tolerability; supporting development of ALTO-207 in ~7...

ANRO : 28.78 (+1.73%)
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression

— Phase 2b closely resembles PAX-D study design, which demonstrated an effect size for pramipexole more than two times larger than approved TRD therapies — — Trial...

ANRO : 28.78 (+1.73%)
Stocks Recover on Hopes Strait of Hormuz Could Soon Reopen

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed up +0.11%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.11%. June E-mini...

ALK : 48.40 (+2.41%)
APO : 140.28 (+6.26%)
UAL : 126.31 (+2.06%)
ARES : 143.11 (+3.96%)
CARR : 63.62 (+0.28%)
$IUXX : 29,525.48 (unch)
ZNU26 : 108-190 (+0.10%)
MTDR : 52.62 (+0.75%)
TSLA : 332.81 (+0.58%)
ESU26 : 7,765.75 (+0.24%)
NCLH : 18.70 (+0.81%)
BX : 147.17 (+3.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Alto Neuroscience Inc. is a clinical-stage biopharmaceutical company. Its clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia and other mental health conditions. Alto Neuroscience Inc. is based in LOS ALTOS, Calif.

See More

Key Turning Points

3rd Resistance Point 31.05
2nd Resistance Point 30.05
1st Resistance Point 29.42
Last Price 28.78
1st Support Level 27.79
2nd Support Level 26.79
3rd Support Level 26.16

See More

52-Week High 29.49
Last Price 28.78
Fibonacci 61.8% 19.38
Fibonacci 50% 16.25
Fibonacci 38.2% 13.13
52-Week Low 3.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.